0A

IGEA Pharma NVLSE IGEA Pharma Stock Report

Last reporting period 30 Jun, 2022

Updated —

Last price

Market cap $B

0.074

Micro

Exchange

XLON - London Stock Exchange

0AAX.L Stock Analysis

0A

Uncovered

IGEA Pharma NV is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-19/100

Low score

Market cap $B

0.074

Dividend yield

Shares outstanding

337.03 B

IGEA Pharma NV is a health-tech company focused on measure and control of test factors related to life-threatening diseases. The company is headquartered in Hoofddorp, Noord-Holland. The company went IPO on 2018-12-20. The firm focuses on research and development of biomedical solutions for the prevention of diabetes and Alzheimer's disease. Its offering portfolio includes medical testing devices and dietary supplements. The firm develops ALZ-1 Test, a blood test to measure and control level of free copper, also known as Free Copper II or Non-Ceruloplasmin Copper in the bloodstream, which is a major recognized modifiable risk factor for the Alzheimer’s disease. The firm offers its services in the Netherlands.

View Section: Eyestock Rating